It’s been a crucial week for HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM); here’s what analysts have to say.

April 21, 2018 - By Adrian Mccoy

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Logo

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Ratings Coverage

Among 2 analysts covering HTG Molecular Diagnostics (NASDAQ:HTGM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. HTG Molecular Diagnostics had 10 analyst reports since November 8, 2017 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Thursday, February 1. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, November 8 report. The firm earned “Buy” rating on Friday, March 23 by H.C. Wainwright. As per Friday, January 5, the company rating was maintained by H.C. Wainwright. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, April 17. The firm has “Buy” rating given on Friday, March 23 by Canaccord Genuity. Canaccord Genuity maintained the shares of HTGM in report on Friday, January 5 with “Buy” rating. Canaccord Genuity maintained the stock with “Buy” rating in Monday, January 8 report. The stock of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has “Buy” rating given on Wednesday, January 24 by H.C. Wainwright. The company was maintained on Wednesday, December 27 by H.C. Wainwright. Below is a list of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) latest ratings and price target changes.

17/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
23/03/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $5 New Target: $7 Maintain
23/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
24/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
08/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $5.0 Maintain
05/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $5.0 Maintain
05/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
27/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
08/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain

The stock increased 1.78% or $0.06 during the last trading session, reaching $3.44. About 681,342 shares traded. HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has declined 59.58% since April 21, 2017 and is downtrending. It has underperformed by 71.13% the S&P500.

HTG Molecular Diagnostics, Inc. develops and markets services and products based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company has market cap of $97.54 million. The companyÂ’s products, HTG Edge and HTG EdgeSeq platforms include instrumentation , consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies. It currently has negative earnings. The Company’s platforms generate a molecular profiling library for detection using next-generation sequencing.

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: